An observational study on use of maternal risk factors, mean arterial pressure, mean uterine artery pulsatility index and serum placenta like growth factor for screening of preeclampsia in first trimester
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20232717Keywords:
Biochemical screening, First trimester screening, Preeclampsia screening, Screening in early pregnancyAbstract
Background: Preeclampsia (PE) affects 2-3% of all pregnancies and is a major cause of maternal and perinatal morbidity and mortality. In the last decade extensive research has been devoted to screening for PE with the aim of reducing the prevalence of the disease through pharmacological intervention in the high-risk group. In our study we used the combined screening method to evaluate the risk of developing preeclampsia in pregnant women. Our primary objective was to estimate the screen positivity rate for preeclampsia using the first trimester combined screening method (maternal risk factors and biophysical methods) in our population in a tertiary care hospital setting.
Methods: Risk of preeclampsia was calculated using fetal medicine foundation algorithm accessed at https://fetalmedicine.org/research/assess/preeclampsia.
Results: Using the combined screening method, 10 out of 75 women (13.33%) were found to be screen positive for risk of developing preterm preeclampsia (at <37 weeks) with a risk cut off of 1:100. Using the maternal risk factors approach only (as per NICE guidelines) again 10 out of 75 women (13.3%) were found to be screen positive. However, the subset of women who were screen positive by each method were not the same. There were only 4 out of 10 women who were screen positive by both methods. The screen positivity rate for preterm preeclampsia (<37 weeks) in our population using combined screening approach was 13%, which means aspirin would be advisable to 13/100 pregnant women to reduce the risk of preterm preeclampsia.
Conclusions: Basis on our study we concluded that one cost effective method of screening could be, to offer aspirin to all women who are screen positive by the maternal risk factor approach (NICE guidelines approach). This approach does not require any extra blood test or skill to measure uterine artery pulsatility index.
References
Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol. 2009;113(6):1299-306.
Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). The definition of severe and early-onset preeclampsia. Pregnancy Hypertens. 2013;3(1):44-7.
Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, et al. Erratum to “the International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention” [Int J Gynecol Obstet. 2019;145(1):1-33]. Int J Gynaecol Obstet. 2019;146(3):390-1.
Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24-43.
Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1-7.
Sanjay G, Girija W. Preeclampsia-eclampsia. J Obstet Gynecol India. 2014;64(1):4-13.
WHO recommendations for prevention and treatment of preeclampsia and eclampsia: 2013 WHO/RHR 14.17
Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention Int J Gynecol Obstet. 2019;145(1):1-33
O’Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, et al. Multicenter screening for pre‐eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49(6):756-60.
Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, et al. Aspirin for evidence based preeclampsia prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol. 2017;217:685.
Tan MY, Syngelaki A, Poon LC, Rolnik DL, O'Gorman N, Delgado JL, et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. Ultrasound Obstet Gynecol. 2018;52(2):186-95.
